Meeting
2021 ASCO Annual Meeting
Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.
Authors
Beverly Moy
Massachusetts General Hospital Cancer Center, Boston, MA
Beverly Moy , Masato Takahashi , Shoichiro Ohtani , Ewa Chmielowska , Naohito Yamamoto , Bruno P. Coudert , Feng Xu , Alvin F. Wong , Arlene Chan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT00878709
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 540)
DOI
10.1200/JCO.2021.39.15_suppl.540
Abstract #
540
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early‑stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.
First Author: Bent Ejlertsen
Poster
2015 Breast Cancer Symposium
Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.
First Author: Arlene Chan
Poster
2018 ASCO Annual Meeting
Duration of extended adjuvant therapy with neratinib in early‑stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial.
First Author: Michael Gnant
Poster
2021 ASCO Annual Meeting
Lisinopril or carvedilol in prevention of trastuzumab-induced cardiotoxicity in patients with HER2-positive early stage breast cancer: Longitudinal changes of left ventricular ejection fraction below normal levels (LVEF <50%).
First Author: Pamela N. Munster